ORIC Pharmaceuticals ORIC

$ 9.28 -2.11%

Quarterly report 2024-Q2
added 08-12-2024

ORIC Pharmaceuticals Financial Statements 2011-2024 | ORIC

Annual Financial Statements ORIC Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	771 M	201 M	558 M	889 M	-	-	-	-	-	-	-	-	-
Shares	51.5 M	39.7 M	38 M	30.3 M	-	-	-	-	-	-	-	-	-
Historical Prices	15	5.07	14.7	33.9	-	-	-	-	-	-	-	-	-
Net Income	-101 M	-89.1 M	-78.7 M	-73.7 M	-26.9 M	-21.4 M	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-111 M	-91.8 M	-78.9 M	-74.2 M	-28.6 M	-22.4 M	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-110 M	-90.8 M	-78 M	-73.2 M	-27.5 M	-21.5 M	-	-	-	-	-	-	-
Operating Expenses	111 M	91.8 M	78.9 M	74.2 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	25.6 M	25.1 M	22 M	13.4 M	5.72 M	3.34 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement ORIC Pharmaceuticals

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	70.3 M	67.3 M	54.9 M	57.4 M	45.7 M	45.1 M	45.1 M	39.6 M	39.5 M	39.4 M	39.4 M	39 M	36.7 M	36.7 M	36.7 M	30.3 M	21.6 M	1.99 M	1.98 M	1.95 M	1.87 M	1.81 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-32 M	-25 M	-	-25.5 M	-22.9 M	-23.9 M	-	-24.8 M	-20.3 M	-23.2 M	-	-18.4 M	-21 M	-16.5 M	-	-25.5 M	-11 M	-8.87 M	-	-6.55 M	-5.96 M	-6.02 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-36 M	-29 M	-	-28.7 M	-25 M	-25.7 M	-	-25.7 M	-20.7 M	-23.3 M	-	-18.5 M	-21.1 M	-16.6 M	-	-25.6 M	-11.1 M	-9.18 M	-	-7.1 M	-6.36 M	-6.35 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-28.7 M	-	-	-	-25.4 M	-	-25 M	-20.2 M	-23 M	-	-17.8 M	-20.6 M	-16.3 M	-	-24.9 M	-10.6 M	-8.93 M	-	-6.34 M	-5.87 M	-6.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	36 M	29 M	-	28.7 M	25 M	25.7 M	-	25.7 M	20.7 M	23.3 M	-	18.5 M	21.1 M	16.6 M	-	25.6 M	11.1 M	9.18 M	-	7.1 M	6.36 M	6.35 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	7.08 M	7.03 M	-	6.29 M	6.2 M	6.16 M	-	5.97 M	6.86 M	6.43 M	-	5.56 M	5.54 M	4.86 M	-	3.8 M	3.4 M	1.92 M	-	1.46 M	1.32 M	1.13 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency